Is Wegovy Being Discontinued? The Facts for UK Patients

What triggers the 'Wegovy discontinued' search in the first place

Most people land on this question for one of three reasons: a pharmacy has told them a particular dose is out of stock, a news story about Wegovy being withdrawn in another market has appeared in their feed, or their pen has arrived late and they are trying to work out whether to switch treatments. None of those scenarios means Wegovy is gone from the UK.

Novo Nordisk has at various points paused the launch of Wegovy in certain countries while prioritising supply to markets already running. That strategic sequencing generated international headlines that were technically accurate in context but alarming without it. In the UK, Wegovy launched and has remained available through the licensed supply chain. The NICE appraisal of semaglutide for weight management (published as NICE technology appraisal TA875) also remains active, which would not be the case if the medicine were being withdrawn.

Dose shortages are a separate issue. Individual pen strengths, particularly at the lower end of the titration schedule, have been periodically constrained. A shortage of the 0.25 mg or 0.5 mg pen is not the same as the medicine being discontinued; it is a manufacturing and distribution lag. Your prescriber's job in that situation is to advise on whether to pause, hold at your current dose, or consider an alternative, not yours to decide alone.

What has actually changed in the Wegovy range recently

The Wegovy range has expanded, not contracted. On 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg pen, one pre-set weekly injection with a built-in covered needle that locks after use, designed for adults with a BMI of 30 or above. This is the highest available semaglutide dose for weight management in the UK. Trials reported an average weight loss of around 20.7% over 72 weeks at 7.2 mg, which narrows the gap with the results seen for tirzepatide at its highest dose. You can read the MHRA's announcement on GOV.UK for the detail.

Then on 11 June 2026, the MHRA approved Wegovy tablets (oral semaglutide) making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet is taken first thing in the morning before food, with a small amount of plain water, and requires no refrigeration. For people who keep the injection pen in the fridge door alongside everyday essentials, the tablet offers a genuinely different routine. That approval expanded who might benefit from semaglutide-based treatment, particularly those who prefer not to inject. If the distinction between Wegovy injections and the newer tablet format is relevant to you, our Wegovy overview covers both.

For broader context on how semaglutide works as a medicine, that page sets out the mechanism clearly, and if you are curious about how semaglutide was discovered in the first place, that story traces the research path that led to the medicine used in Wegovy today.

If your specific dose is currently unavailable: what matters when deciding next steps

The practical decision most people face is not whether Wegovy is discontinued but what to do when their pharmacist cannot fulfil a specific strength. The considerations are worth separating clearly.

First, pausing at your current dose is often preferable to skipping doses entirely. Missing multiple consecutive injections can result in a return of appetite, and re-titrating from scratch takes time. A prescriber should advise you before you make that call. Second, switching to an alternative licensed medicine (such as other weight-loss treatments available in the UK) is a clinical decision, not a self-service one. Tirzepatide (Mounjaro) is the other injectable option currently licensed in the UK for weight management; a prescriber reviews your history before recommending any switch. Third, checking the semaglutide discontinuation page gives a fuller picture of how supply disruptions have played out historically, alongside background on the semaglutide discovery that explains why this class of medicine took the particular scientific path it did.

None of this requires you to act in a rush. The FAQ section covers common supply questions. If you want a clinical view specific to your situation, a consultation with one of our prescribers is the right starting point, see our clinical team for who reviews cases at nume. And if cost is part of your thinking as you weigh up options, our Wegovy cost guide sets out what private treatment typically involves.

Wegovy is a prescription-only medicine. Any decision about pausing, switching or restarting treatment should be made with a GPhC-registered prescriber who can review your full clinical picture. If you are ready to discuss your options, you are welcome to start your free consultation with nume's clinical team today.